Sustiva, Efavirenz News

Brazilian Health Minister Jose Gomes Temporao on Wednesday said Brazil will begin producing a generic version of Merck's antiretroviral efavirenz, the AP/USA Today reports.

Brazil said on Wednesday it will start producing a generic version of a key AIDS drug, the latest step in the country's long-running battle with pharmaceutical giants to bring down the cost of treatment for HIV ...

Body fat changes and other metabolic complications are a growing concern for people with HIV , especially those on HAART .

However, other therapeutic strategies could be beneficial given the long-term toxicities and quality of life issues associated with taking multiple antiretroviral drugs for many years.

The commonly used antiretroviral drug efavirenz also frequently produces neuropsychiatric side effects, ranging from depression to insomnia to unusual dreams or nightmares.

More Treatment News September 4, 2008 A person's genetic sequence, and not his or her race, should guide scientists and health care providers in the design of clinical trials and treatment decisions with ...

A new nucleoside reverse transcriptase inhibitor , etravirine has received marketing approval in the European Union, manufacturer Tibotec announced last week.

Depot Formulation of Rilpivirine May Offer Months of Sustained Anti-HIV Activity with a Single Injection By Liz Highleyman Researchers at the XVII International AIDS Conference this month in Mexico City ...

To the Editor: In their study comparing three different regimens for initial treatment of human immunodeficiency virus type 1 infection, Riddler et al.

The FDA last week announced that the atazanavir package insert has been updated to include important information about drug-drug interactions regarding the co-administration of atazanavir boosting) and ...

More Treatment News The U.S. Food and Drug Administration issued new instructions on potential drug interactions between the protease inhibitor Reyataz and several other types of medications, including ...

Next generation first-line NNRTI, rilpivirine potent; lowest dose better-tolerated than efavirenz at 96 weeks Edwin J. Bernard , Tuesday, August 19, 2008 Tibotec's next-generation NNRTI, rilpivirine continues ...

Are Abacavir/lamivudine and Tenofovir/emtricitabine Equally Effective as NRTI Backbones? ACTG 5202 and HEAT Disagree With more than 20 antiretroviral drugs to choose from, one of the most frequently asked ...

Co-administration of ART and anti-tubercular therapy may be complicated by shared toxicity or adverse drug interactions, according to background information in the article.

Two new non-nucleoside reverse transcriptase inhibitors have demonstrated good antiviral efficacy and favourable safety profiles in seven-day monotherapy trials, according to late-breaker presentations Thursday ...

Raltegravir Continues to Demonstrate Viral Load Suppression and Good Tolerability at 96 Weeks in Treatment-naive Patients Raltegravir is the first HIV integrase inhibitor, approved for treatment-experienced ...

Investigational Next-generation NNRTI Rilpivirine Demonstrates Potent Antiviral Activity at 96 Weeks in Treatment-naive Patients Tibotec's investigational next-generation non-nucleoside reverse transcriptase ...

More Treatment News by Tim Horn New 96-week data from a clinical trial of Isentress , Merck's integrase inhibitor approved for treatment-experienced patients by the U.S. Food and Drug Administration in October ...

The integrase inhibitor raltegravir continues to show strong efficacy "almost identical" to that of efavirenz at 96 weeks, in combination with tenofovir and 3TC, and a side-effect profile that continues to be ...

The antiretroviral drug nevirapine is less effective in people with HIV/tuberculosis coinfection who begin taking nevirapine at the same time as the TB treatment rifampicin, according to a study published in ...